|
시장보고서
상품코드
2058258
항정신병 약물 시장 : 질환별, 약물별, 치료 분류별, 유통 채널별, 지역별Antipsychotic Drugs Market, By Disease, By Drug, By Therapeutic Class,By Distribution Channel, By Geography |
||||||
항정신병 약물 시장은 2026년에 194억 달러로 추정되며, 2033년까지 322억 4,000만 달러에 달할 것으로 예상됩니다. 2026년부터 2033년까지 CAGR 7.5%로 성장할 것으로 전망됩니다.
| 보고서 범위 | 보고서 상세 | ||
|---|---|---|---|
| 기준 연도: | 2025년 | 2026년 시장 규모: | 194억 달러 |
| 과거 데이터 기간: | 2020-2024년 | 예측 기간: | 2026-2033년 |
| 2026년부터 2033년까지 예측 기간 CAGR: | 7.50% | 2033년 시장 규모 예측: | 322억 4,000만 달러 |
조현병, 양극성 장애, 정신병 등 정신 질환으로 인한 전 세계적 부담이 증가하는 데다, 이에 대한 인식이 높아지고 진단율이 상승하며 장기적인 약물 치료 전략에 대한 수용이 확대되고 있는 것을 배경으로, 시장은 꾸준히 성장하고 있습니다.
항정신병 약물은 신경전달물질, 특히 도파민과 세로토닌 경로의 활동을 조절함으로써 환각, 망상, 기분 불안정 등의 증상을 억제하며, 중증 정신질환의 관리에 있어 매우 중요한 역할을 하고 있습니다. 이 시장에는 1세대(전형) 및 2·3세대(비전형) 항정신병 약물이 포함되어 있으며, 효능 향상과 부작용 프로파일 감소로 인해 비전형 약물이 점점 더 선호되고 있습니다.
의약품 개발 분야의 기술적 진보, 특히 장기 작용형 주사제(LAI) 제형과 새로운 비정형 분자들은 환자의 복약 순응도를 높이고 재발률을 낮춤으로써 치료 성과를 혁신하고 있습니다. 또한, 혁신적인 치료법에 대한 규제 당국의 지원 확대와 맞춤형 정신과 의료에 대한 관심 증대가 전 세계 시장의 성장 전망을 더욱 견고하게 하고 있습니다.
시장 역학
항정신병 약물 시장은 임상적, 인구통계학적, 규제적 요인들이 복합적으로 작용하여 견조한 성장세를 보이고 있습니다. 주요 촉진요인 중 하나는 전 세계 정신 질환 유병률의 증가입니다. 조현병만 해도 전 세계적으로 2,000만 명 이상에게 영향을 미치고 있으며, 양극성 장애 및 관련 정신병성 질환 역시 장기적인 장애의 주요 원인으로 남아 있어 항정신병 약물 치료에 대한 지속적인 수요를 창출하고 있습니다.
또 다른 주요 성장 요인은 고령 인구의 증가입니다. 고령자는 치매와 관련된 정신 질환이나 항정신병 약물 치료가 필요한 기타 신경정신과적 질환에 걸리기 쉬운 경향이 있습니다. 또한, 특히 신흥국에서 정신건강 치료에 대한 인식이 높아지고 편견이 줄어드는 것도 진단율과 치료율 향상에 기여하고 있습니다.
또한, 제제의 지속적인 혁신도 시장을 견인하고 있습니다. 서방형 주사용 항정신병 약물은 복약 순응도 향상과 입원율 감소로 인해 널리 사용되고 있습니다. 또한, 새로운 비전형 항정신병 약물과 서방형 제제의 도입으로 치료 성과가 향상되었으며, 임상의의 치료 선택지가 넓어지고 있습니다.
그러나 부작용, 환자의 복약 순응도 저하, 그리고 새로운 치료법에 대한 보험 급여 제한과 같은 과제들이 여전히 시장 성장을 어느 정도 저해하고 있습니다. 이러한 과제들, 의료비 지출 증가, 정신건강 프로그램 확충, 그리고 탄탄한 개발 파이프라인 덕분에 장기적인 시장 성장이 지속될 것으로 예상됩니다.
본 조사의 주요 특징
- 본 조사에서는 각 부문의 잠재적 수익 기회를 파악하고, 이 시장에서 매력적인 투자 제안 매트릭스에 대해 설명하고 있습니다.
- 또한, 본 조사에서는 시장 촉진요인, 억제요인, 기회, 신제품 출시, 시장 동향, 지역별 전망 및 주요 기업들이 채택하는 경쟁 전략에 관한 중요한 인사이트를 제공합니다.
- 본 조사에서는 항정신병약 시장의 주요 기업에 대해 기업 개요, 서비스 포트폴리오, 주요 발전 사항, 재무 실적 및 전략과 같은 지표를 바탕으로 프로필을 작성하고 있습니다.
- 본 보고서의 인사이트를 활용함으로써, 마케팅 담당자와 경영진은 향후 서비스 혁신, 시장 확대, 전략적 제휴와 관련하여 정보에 기반한 의사결정을 내릴 수 있게 됩니다.
- 항정신병약 시장 보고서는 투자자, 서비스 제공업체, 제약회사, 규제 당국, 금융 애널리스트 등 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 항정신병 약물 시장 평가에 사용되는 체계적인 분석 프레임워크나 전략 매트릭스를 활용함으로써 큰 이점을 얻을 수 있습니다.
목차
제1장 조사 목적과 가정
제2장 시장 전망
제3장 시장 역학·규제·동향 분석
제4장 세계의 항정신병 약물 시장 : 질환별, 2021-2033년
제5장 세계의 항정신병 약물 시장 : 약물별, 2021-2033년
제6장 세계의 항정신병 약물 시장 : 치료 분류별, 2021-2033년
제7장 세계의 항정신병 약물 시장 : 유통 채널별, 2021-2033년
제8장 세계의 항정신병 약물 시장 : 지역별, 2021-2033년
제9장 경쟁 구도
제10장 섹션
KSM 26.06.19Antipsychotic Drugs Market is estimated to be valued at USD 19.4 Bn in 2026 and is expected to reach USD 32.24 Bn by 2033, growing at a compound annual growth rate (CAGR) of 7.5% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 19.4 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 7.50% | 2033 Value Projection: | USD 32.24 Bn |
The market is experiencing steady expansion driven by the rising global burden of mental health disorders such as schizophrenia, bipolar disorder, and psychosis, alongside increasing awareness, diagnosis rates, and acceptance of long-term pharmacological treatment strategies.
Antipsychotic drugs play a critical role in managing severe psychiatric conditions by regulating neurotransmitter activity, particularly dopamine and serotonin pathways, to control symptoms such as hallucinations, delusions, and mood instability. The market includes both first-generation (typical) and second- and third-generation (atypical) antipsychotics, with atypical drugs increasingly preferred due to improved efficacy and reduced side-effect profiles.
Technological advancements in drug development, particularly long-acting injectable (LAI) formulations and novel atypical molecules, are transforming treatment outcomes by improving patient adherence and reducing relapse rates. Additionally, growing regulatory support for innovative therapies and increasing focus on personalized psychiatric care are further strengthening market growth prospects across global regions.
Market Dynamics
The Antipsychotic Drugs Market is witnessing robust growth due to multiple converging clinical, demographic, and regulatory factors. A key driver is the increasing prevalence of mental health disorders worldwide. Schizophrenia alone affects over 20 million people globally, while bipolar disorder and related psychotic conditions continue to contribute significantly to long-term disability, creating sustained demand for antipsychotic therapies.
Another major growth factor is the rising geriatric population, which is more susceptible to dementia-related psychosis and other neuropsychiatric conditions requiring antipsychotic intervention. Expanding awareness and reduced stigma around mental health treatment are also contributing to higher diagnosis and treatment rates, especially in emerging economies.
The market is further supported by continuous innovation in drug formulations. Long-acting injectable antipsychotics are gaining strong adoption due to improved medication adherence and reduced hospitalization rates. Additionally, the introduction of newer atypical antipsychotics and extended-release formulations is enhancing treatment outcomes and expanding therapeutic options for clinicians.
However, challenges such as adverse side effects, patient non-adherence, and reimbursement limitations for newer therapies continue to restrain market growth to some extent. Despite these challenges, increasing healthcare expenditure, expansion of mental health programs, and strong regulatory pipelines are expected to sustain long-term market expansion.
Key Features of the Study
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the Antipsychotic Drugs Marketbased on the following parameters - company highlights, service portfolio, key developments, financial performance, and strategies
- Key companies covered as a part of this study include H. Lundbeck A/S; Otsuka Pharmaceutical Co., Ltd.; Janssen Pharmaceuticals, Inc.; Eli Lilly and Company; AbbVie, Inc.; Teva Pharmaceutical Industries Ltd.; Dr. Reddy's Laboratories Ltd.; Sumitomo Pharma Co., Ltd.; Alkermes; Bristol-Myers Squibb Company
- Insights from this report would allow marketers and management authorities to make informed decisions regarding future service innovations, market expansion, and strategic partnerships
- The Antipsychotic Drugs Market report caters to various stakeholders including investors, service providers, pharmaceutical companies, regulatory bodies, and financial analysts
- Stakeholders would benefit from structured analytical frameworks and strategy matrices used in evaluating the Antipsychotic Drugs Market
Market Segmentation
- By Disease (Revenue, USD Bn, 2026-2033)
- Schizophrenia
- Bipolar Disorder
- Unipolar Depression
- Dementia
- Others
- By Drug (Revenue, USD Bn, 2026-2033)
- Risperidone
- Quetiapine
- Olanzapine
- Aripiprazole
- Brexpiprazole
- Paliperidone Palmitate
- Others
- By Therapeutic Class (Revenue, USD Bn, 2026-2033)
- First Generation
- Second Generation
- Third Generation
- By Distribution Channel (Revenue, USD Bn, 2026-2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Region (Revenue, USD Bn, 2026-2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC
- Israel
- Rest of Middle East
- Africa
- South Africa
- Central Africa
- North Africa
- Company Profiles
- Lundbeck A/S
- Otsuka Pharmaceutical Co., Ltd.
- Janssen Pharmaceuticals, Inc.
- Eli Lilly and Company
- AbbVie, Inc.
- Teva Pharmaceutical Industries Ltd.
- Reddy's Laboratories Ltd.
- Sumitomo Pharma Co., Ltd.
- Alkermes
- Bristol-Myers Squibb Company
Table of Contents
1. Research Objective and Assumption
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Disease
- Market Snippet, By Drug
- Market Snippet, By Therapeutic Class
- Market Snippet, By Distribution Channel
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Key Developments
- Technological Advancement
- Regulatory Scenario
4. Global Antipsychotic Drugs Market, By Disease, 2021- 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
- Schizophrenia
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Bipolar Disorder
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Unipolar Depression
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Dementia
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
5. Global Antipsychotic Drugs Market, By Drug, 2021 - 2033 (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
- Risperidone
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Quetiapine
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Olanzapine
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Aripiprazole
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Brexpiprazole
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Paliperidone Palmitate
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
6. Global Antipsychotic Drugs Market, By Therapeutic Class 2021- 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- First Generation
- Introduction
- Market Size, Volume and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Second Generation
- Introduction
- Market Size, Volume and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Third Generation
- Introduction
- Market Size, Volume and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
7. Global Antipsychotic Drugs Market, By Distribution Channel 2021- 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size, Volume and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Retail Pharmacies
- Introduction
- Market Size, Volume and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Online Pharmacies
- Introduction
- Market Size, Volume and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
8. Global Antipsychotic Drugs Market, By Region, 2021- 2033, (USD Bn)
- Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Regions, 2022-2033
- North America
- Market Size and Forecast, By Disease, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Drug, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Therapeutic Class, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, (USD Bn)
- U.S.
- Canada
- Latin America
- Market Size and Forecast, By Disease, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Drug, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Therapeutic Class, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, (USD Bn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Market Size and Forecast, By Disease, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Drug, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Therapeutic Class, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, (USD Bn)
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Market Size and Forecast, By Disease, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Drug, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Therapeutic Class, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, (USD Bn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of APAC
- Middle East
- Market Size and Forecast, By Disease, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Drug, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Therapeutic Class, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, (USD Bn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Market Size and Forecast, By Disease, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Drug, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Therapeutic Class, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, (USD Bn)
- South Africa
- Central Africa
- North Africa
9. Competitive Landscape
- Company Profiles
- H. Lundbeck A/S
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Otsuka Pharmaceutical Co., Ltd.
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Janssen Pharmaceuticals, Inc.
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Eli Lilly and Company
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- AbbVie, Inc.
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Teva Pharmaceutical Industries Ltd.
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Dr. Reddy's Laboratories Ltd.
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Sumitomo Pharma Co., Ltd.
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Alkermes
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Bristol-Myers Squibb Company
- Company Overview
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- H. Lundbeck A/S
10. Section
- References
- Research Methodology
- About us and Sales Contact
